echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > First CLL patient to receive CAR T-cell therapy reaches 10-year complete remission

    First CLL patient to receive CAR T-cell therapy reaches 10-year complete remission

    • Last Update: 2022-04-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Article from NEJM Journal Watch A Decade of Remission After Immunotherapy for Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia Reaches 10 Years of Remission after Immunotherapy Review by Anthony L.
    Komaroff, MD Two Cases of Aggressive CLL Patients Long-term complete remission was achieved after receiving CAR T-cell therapy

    Cancer immunotherapy has had some exciting short-term victories (NEJM JW Gen Med Jun 16 2015)

    But how long will these successes last? University of Pennsylvania leads the way in chimeric antigen receptor (CAR) T-cell therapy, with researchers reporting two cases of aggressive chronic lymphocytic leukemia (CLL) among the first patients to receive CAR T-cell therapy The patient has been in remission for 10 years

    In CAR T-cell therapy, a cancer patient's T cells are engineered in a laboratory dish, and the engineered T cells contain receptors that bind to specific antigens on the patient's tumor cells

    The engineered "personalized" CAR T cells are then grown in large numbers and infused back into the patient, where they bind, attack and destroy tumor cells

    Two patients with aggressive CLL who received CAR T-cell therapy 10 years ago are still alive and have no evidence of residual leukemia cells

    They had persistent CD4+ CAR T cell populations that remained functionally active, able to attack relapsed leukemia cells and maintain complete remission, with no apparent adverse effects

    Comments CAR T-cell therapy has achieved complete remission at 10 years in at least two patients with aggressive CLL

    The most likely reason is that the CAR T cell population is still alive and able to recognize and clear leukemia cells

    Reviewed article Melenhorst JJ et al.
    Decade-long leukaemia remissions with persistence of CD4+ CAR T cells.
    Nature 2022 Feb 2; [e-pub].
    1038/s41586-021-04390-6 ) Related readings NEJM Journal Watch NEJM Journal Watch (NEJM Journal Watch) is published by the NEJM Group.
    It invites internationally renowned doctors to comment on important papers in the medical field and helps doctors understand and apply the latest developments

    "NEJM Frontiers of Medicine" translates several articles every week, publishes them on the app and official website, and selects 2-3 articles and publishes them on WeChat

    Copyright Information This article was translated, written or commissioned by the NEJM Frontiers in Medicine, jointly created by Jiahui Medical Research and Education Group (J-Med) and The New England Journal of Medicine (NEJM)

    The full text of the Chinese translation and the included figures are exclusively authorized by the NEJM Group

    If you want to reprint, please leave a message or contact nejmqianyan@nejmqianyan.

    Unauthorized translation is an infringement, and the copyright owner reserves the right to pursue legal responsibility

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.